These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30855134)

  • 21. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
    Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
    Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural characterization of a mutated, ADCC-enhanced human Fc fragment.
    Oganesyan V; Damschroder MM; Leach W; Wu H; Dall'Acqua WF
    Mol Immunol; 2008 Apr; 45(7):1872-82. PubMed ID: 18078997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds.
    Wozniak-Knopp G; Stadlmann J; Rüker F
    PLoS One; 2012; 7(1):e30083. PubMed ID: 22272277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly.
    Farràs M; Miret J; Camps M; Román R; Martínez Ó; Pujol X; Erb S; Ehkirch A; Cianferani S; Casablancas A; Cairó JJ
    MAbs; 2020; 12(1):1702262. PubMed ID: 31876436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography-mass spectrometry.
    Lippold S; Knaupp A; de Ru AH; Tjokrodirijo RTN; van Veelen PA; van Puijenbroek E; de Taeye SW; Reusch D; Vidarsson G; Wuhrer M; Schlothauer T; Falck D
    MAbs; 2021; 13(1):1982847. PubMed ID: 34674601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species.
    Glover ZK; Wecksler A; Aryal B; Mehta S; Pegues M; Chan W; Lehtimaki M; Luo A; Sreedhara A; Rao VA
    MAbs; 2022; 14(1):2122957. PubMed ID: 36151884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
    Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
    MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence of disulfide bond scrambling during production of an antibody-drug conjugate.
    Liu-Shin LP; Fung A; Malhotra A; Ratnaswamy G
    MAbs; 2018; 10(8):1190-1199. PubMed ID: 30339473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).
    Kainer M; Antes B; Wiederkum S; Wozniak-Knopp G; Bauer A; Rüker F; Woisetschläger M
    Arch Biochem Biophys; 2012 Oct; 526(2):154-8. PubMed ID: 22634259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
    PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.
    Wiggins B; Liu-Shin L; Yamaguchi H; Ratnaswamy G
    J Pharm Sci; 2015 Apr; 104(4):1362-72. PubMed ID: 25631158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A variant human IgG1-Fc mediates improved ADCC.
    Stewart R; Thom G; Levens M; Güler-Gane G; Holgate R; Rudd PM; Webster C; Jermutus L; Lund J
    Protein Eng Des Sel; 2011 Sep; 24(9):671-8. PubMed ID: 21596686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A C-terminal interdomain disulfide bond significantly stabilizes the Fc fragment of IgG.
    Wozniak-Knopp G; Rüker F
    Arch Biochem Biophys; 2012 Oct; 526(2):181-7. PubMed ID: 22483683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.
    Borrok MJ; Mody N; Lu X; Kuhn ML; Wu H; Dall'Acqua WF; Tsui P
    J Pharm Sci; 2017 Apr; 106(4):1008-1017. PubMed ID: 28057542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.
    Roberts JT; Barb AW
    J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
    Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.
    Arora J; Hu Y; Esfandiary R; Sathish HA; Bishop SM; Joshi SB; Middaugh CR; Volkin DB; Weis DD
    MAbs; 2016; 8(8):1561-1574. PubMed ID: 27560842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.
    Pace D; Lewis N; Wu T; Gillespie R; Leiske D; Velayudhan J; Rohrbach A; Connell-Crowley L
    Biotechnol Prog; 2016 Sep; 32(5):1181-1192. PubMed ID: 27160519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.